TICKERNERD
Menu
CAMPCAMPHealthcare · Biotechnology

CAMP Stock Forecast: CAMP4 Therapeutics Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.48
+0.45% on the day

The 7 Wall Street analysts covering CAMP4 Therapeutics Corp. hold a median 12-month price target of $8.5 — +89.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$281.1M
Ticker Nerd rank
59 / 100
Median analyst target
$8.50
Analysts covering
7
Total return, dividends reinvested
1W
−17.6%
1M
+40.4%
YTD
−26.9%
1Y
+181.8%
From 52W high
−37.2%
From 52W low
+217.7%
$1.41
$7.13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CAMP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CAMP4 Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
90
Growth
83
Momentum
76
Size
63
Issuance
46
Value
45
Revisions
37
Quality
34
Volatility
10

Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CAMP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CAMP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26CAMPHigh $15.00Median $8.50Low $6.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $6.50Median $8.50High $15.00

The green dot is the last close — the median target sits +89.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
14 Aug 2026Piper SandlerReiteratesOverweight$12 → $15
16 June 2026JP MorganUpgradeOverweight—
16 June 2026JP MorganUpgradeOverweight$5.00 → $9.00
10 June 2026Chardan CapitalInitiatesBuy—
10 June 2026Chardan CapitalInitiatesBuy$6.50
14 Apr 2026Rodman & RenshawInitiatesBuy—
2 Apr 2026Leerink PartnersMaintainsOutperform—
2 Oct 2025Cantor FitzgeraldInitiatesOverweight—
16 Sept 2025JP MorganDowngradeNeutral—
15 Sept 2025Piper SandlerMaintainsOverweight—
27 May 2025WedbushInitiatesOutperform—
5 Nov 2024JP MorganInitiatesOverweight—
5 Nov 2024Leerink PartnersInitiatesOutperform—
5 Nov 2024Piper SandlerInitiatesOverweight—
5 Nov 2024William BlairInitiatesOutperform—
11 Jan 2024Goldman SachsMaintainsSell$0.35 → $0.30
9 Oct 2023Goldman SachsMaintainsSell$0.80 → $0.35
6 Oct 2023Craig-HallumDowngradeHold$0.50
6 Oct 2023Roth MKMMaintainsBuy$6.00 → $5.00
29 Aug 2023Roth MKMReiteratesBuy$6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAMP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CAMP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

CAMP4 Therapeutics Corp. (CAMP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 84% of US stocks

Price / sales
66.7×

Cheaper than 5% of US stocks

Price / book
8.4×

Cheaper than 12% of US stocks

EV / EBITDA
−3.9×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
18.8%

Higher than 68% of US stocks

Earnings growth (YoY)
50.8%

Higher than 75% of US stocks

Gross margin
—
Operating margin
−752.1%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−545.9%

Higher than 3% of US stocks

Return on assets
−45.3%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CAMP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CAMPCAMP4 Therapeutics Corp.$281.1M
59
ELDNEledon Pharmaceuticals, Inc.$280.4M
34
ALXOALX Oncology Holdings, Inc.$282.1M
63
TTRXTurn Therapeutics, Inc.$278.6M
17
SRZNSurrozen, Inc.$275.6M
77
ACIUAC Immune SA$286.9M
34
VRXAVERAXA Biotech AG$288.1M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CAMP4 Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CAMP news & analysis

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

CAMP4 Therapeutics reported a second-quarter loss of $0.22 per share, narrower than the $0.24 loss expected by the Zacks Consensus Estimate and an improvement from the $0.62 per share loss a year earlier. Revenue topped estimates in the quarter.

Why it matters — A CAMP watcher would note that the company narrowed its loss and beat both consensus and year-ago results, indicating improving financial performance.

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

GlobeNewsWire · 13 Aug 2026positive

CAMP4 reported its second quarter 2026 financial results and corporate highlights. The company secured regulatory clearance in two jurisdictions to begin its first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder, with trial initiation anticipated in the fourth quarter of this year.

Why it matters — A CAMP watcher would care because obtaining regulatory clearance marks a key step toward advancing CMP-002 into its first clinical trial, a significant milestone for the company's pipeline.

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

CNBC · 6 Aug 2026positive

CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders. The double-blind, placebo-controlled trial will enroll at least 30 children ages 2 to 18, with placebo recipients able to move to treatment if early results are positive.

Why it matters — The news marks advancement of a CAMP4 pipeline candidate for a rare disease into human trials.

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

GlobeNewsWire · 4 Aug 2026positive

CAMP4 Therapeutics announced the second closing of a $100 million private placement, with $50.1 million in proceeds designated to support the advancement of CMP-002 for the treatment of SYNGAP1-related disorder.

Why it matters — The additional capital provides CAMP4 with funding to continue developing its lead candidate CMP-002, a key pipeline asset targeting SYNGAP1-related disorder.

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

GlobeNewsWire · 27 July 2026positive

CAMP4 Therapeutics received clearance from Australia's Therapeutic Goods Administration and a local ethics committee to begin a Phase 1/2 clinical trial of CMP-002, a potential first-in-class disease-modifying therapeutic for SYNGAP1-related disorder. The regulatory milestone also enables the company to raise up to $50 million through a second closing of a previously announced private placement.

Why it matters — The clearance marks a key regulatory step for CAMP4's lead candidate CMP-002 to enter human testing for the first time and also unlocks significant additional funding for the company.

FAQ

Frequently asked questions about CAMP stock

What is the CAMP stock price forecast for 2026-2027?

The 7 Wall Street analysts covering CAMP4 Therapeutics Corp. have a median 12-month price target of $8.5, with estimates ranging from $6.5 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CAMP stock a buy right now?

Of the 7 analysts covering CAMP4 Therapeutics Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CAMP4 Therapeutics Corp. 59 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CAMP?

As at 22 Aug 2026, CAMP4 Therapeutics Corp. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).

Will CAMP stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +89.7% from the last close, and Ticker Nerd's factor model ranks CAMP4 Therapeutics Corp. 59 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CAMP stock forecast for 2030?

No analyst covering CAMP4 Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.5 to $15 over the next 12 months.

How has CAMP stock performed over the past year?

CAMP4 Therapeutics Corp. returned +181.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CAMP4 Therapeutics Corp. do?

Camp4 Therapeutics Corp. is a biotechnology company focused on developing innovative therapeutics by unlocking the potential of gene regulation.

What is the latest news on CAMP?

The most recent item we track (Zacks Investment Research, 13 Aug 2026): "CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates". CAMP4 Therapeutics reported a second-quarter loss of $0.22 per share, narrower than the $0.24 loss expected by the Zacks Consensus Estimate and an improvement from the $0.62 per share loss a year earlier. Revenue topped estimates in the quarter.

Company

About CAMP4 Therapeutics Corp.

Camp4 Therapeutics Corp. is a biotechnology company focused on developing innovative therapeutics by unlocking the potential of gene regulation. The company's core mission is to harness the knowledge of transcriptional machinery and regulatory RNA maps, pioneering in the precision medicine landscape. Camp4 Therapeutics targets a wide array of conditions, primarily genetically driven diseases, by delicately manipulating gene expression to restore normal cellular function. The firm's approach uniquely positions it to impact the broader healthcare and pharmaceutical industries significantly. By translating cutting-edge genomic insights into actionable therapeutic strategies, Camp4 aims to address unmet medical needs and enhance patient outcomes. The company's progress and pipeline developments are closely watched by stakeholders, reflecting its potential to contribute meaningfully to the biotech sector and ultimately, patient care.

CEO Mr. Joshua Mandel-Brehm · 48 employees · United States · https://www.camp4tx.com